Buchheit T, Rauck R
Pain Control Center, Department of Anesthesiology, Wake Forest University, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Curr Rev Pain. 1999;3(3):198-205. doi: 10.1007/s11916-999-0014-0.
For cancer patients who obtain inadequate pain relief with conservative treatment, there is a growing list of effective options for subarachnoid therapy. Morphine and bupivacaine have been the most frequently used drugs for intrathecal infusion, and their use has consistently yielded good results. Despite their effectiveness, however, a therapeutic deficit remains, primarily in the treatment of neuropathic cancer pain. Because of this limitation, more recent research has focused on novel compounds for intrathecal therapy such as clonidine, midazolam, ketamine, and SNX-111. In addition to new drug options, there are various catheter delivery systems from which to choose. In reviewing the literature and experience to date with these various medications and delivery systems, we hope to better aid the clinician in tailoring the best treatment for each patient.
对于经保守治疗后疼痛缓解不足的癌症患者，蛛网膜下腔治疗的有效选择越来越多。吗啡和布比卡因一直是最常用于鞘内输注的药物，其使用始终产生良好效果。然而，尽管它们有效，但仍存在治疗不足，主要是在神经性癌痛的治疗方面。由于这一局限性，最近的研究集中在鞘内治疗的新型化合物上，如可乐定、咪达唑仑、氯胺酮和SNX - 111。除了新的药物选择外，还有各种导管输送系统可供选择。在回顾有关这些各种药物和输送系统的文献及迄今为止的经验时，我们希望能更好地帮助临床医生为每位患者量身定制最佳治疗方案。
